title: Words of wisdom. Re: phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration- resistant prostate cancer commonly remains hormone driven.
authors.affiliation: Department of Urology, Radboud University Nijmegen Medical Center, Postbus 9101, 6500 HB, Nijmegen, the Netherlands. J.Schalken@uro.umcn.nl
authors.forename: Jack A
authors.initials: JA
authors.lastname: Schalken